Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tempus AI

68.34
+2.874.38%
Pre-market: 68.680.3400+0.50%06:30 EDT
Volume:8.25M
Turnover:558.57M
Market Cap:11.83B
PE:-13.89
High:69.25
Open:66.06
Low:65.41
Close:65.47
Loading ...

Eric Lefkofsky, CEO of Tempus AI Inc., Reports Disposal of Common Shares

Reuters
·
23 May

Tempus AI Inc. COO Ryan Fukushima Reports Disposal of Common Shares

Reuters
·
23 May

Erik Phelps, EVP & Chief Admin & Legal Officer, Reports Disposal of Common Shares of Tempus AI Inc

Reuters
·
23 May

Ryan M. Bartolucci, Chief Accounting Officer, Reports Disposal of Tempus AI Inc. Common Shares

Reuters
·
23 May

Stock Track | Tempus AI Plummets 5.05% Despite Upcoming Conference Presentation and Bullish Options Activity

Stock Track
·
22 May

Stock Track | Tempus AI Soars 5.08% on Bullish Options Activity and Upcoming Conference Presentation

Stock Track
·
22 May

Tempus AI Inc. to Present at William Blair Annual Growth Stock Conference

Reuters
·
21 May

tempus AI Inc Class A call volume above normal and directionally bullish

TIPRANKS
·
20 May

Tempus AI, Verastem to Develop Diagnostic Test for Ovarian Cancer Combination Treatment

MT Newswires Live
·
20 May

BRIEF-Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment

Reuters
·
20 May

Tempus AI : Partners With Verastem to Develop Cdx for FDA-Approved Kras-Mutant Recurrent Low-Grade Ovarian Cancer Combination Treatment

THOMSON REUTERS
·
20 May

Tempus AI price target raised to $68 from $48 at BofA

TIPRANKS
·
20 May

Stock Track | Tempus AI Plummets 5.05% Following Major Share Disposal by Enterprise Development

Stock Track
·
16 May

Tempus AI Is Maintained at Neutral by Piper Sandler

Dow Jones
·
16 May

Enterprise Development Unit Offloads Meta Platforms, Tempus AI Shares

MT Newswires Live
·
15 May

Tempus AI Enters Collaboration With Boehringer Ingelheim to Advance Boehringer's Cancer Pipeline

MT Newswires Live
·
14 May

Tempus AI Inc. Announces New Clinical Study to Advance Cancer Treatment through AI-Powered Data Insights

Reuters
·
14 May

Tempus Enters Multi-Year Strategic Collaboration With Boehringer Ingelheim to Advance Its Cancer Pipeline

THOMSON REUTERS
·
14 May

AI Shares Jump. Hims & Hers Health, Tempus AI up 11%; AppLovin up 5%; Palantir up 4%

Tiger Newspress
·
13 May

Tempus AI Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
10 May